Vertex Pharmaceuticals' Revenue Forecast Tops Expectations

Core Insights - Vertex Pharmaceuticals reported fourth-quarter revenue of $2.91 billion, reflecting a 16% year-over-year increase and surpassing analyst expectations [2] - The company anticipates 2025 revenue between $11.75 billion and $12 billion, indicating nearly 20% growth from 2024 at the midpoint, which is significantly above analyst projections [1] - Adjusted earnings for the fourth quarter were $1.04 billion, or $3.98 per share, down from $1.1 billion, or $4.20 per share, a year earlier, slightly missing estimates due to increased operating expenses, lower interest income, and higher tax expenses [2] - The FDA recently approved Vertex's non-opioid painkiller Journavx, marking the first new class of pain medicine approved in over 20 years [3] - Vertex's stock has increased by 12% over the past 12 months as of Monday's close, with shares remaining relatively unchanged in extended trading following the earnings release [3]